Savara (SVRA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting called to order at 3:00 P.M. Eastern Time with executive team and auditor present.
Agenda included formal business, voting on proposals, and a Q&A session for validated stockholders.
Board and executive committee updates
Six directors nominated for re-election to serve until the 2027 annual meeting or until successors are elected.
No other nominations were received; nominations were closed.
Shareholder proposals
Proposal to elect six directors.
Proposal to amend the certificate of incorporation to increase authorized shares from 300 million to 600 million.
Proposal to amend the 2024 Omnibus Incentive Plan to increase shares authorized for issuance by 18,900,000.
Proposal to ratify RSM US LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on compensation of Named Executive Officers.
Latest events from Savara
- MOLBREEVI shows strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market.SVRA
Corporate presentation - Q2 2026 net loss rose to $40.2M as regulatory reviews and launch preparations accelerated.SVRA
Q2 2026 - MOLBREEVI showed strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market.SVRA
Corporate presentation - MOLBREEVI advances toward approval with strong data, new diagnostics, and robust launch plans.SVRA
Leerink’s Global Healthcare Conference 2025 - Molbreevi's positive phase 3 data positions it for US approval and broad APAP market impact.SVRA
Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025 - MOLBREEVI targets a 5,500-patient US market with strong launch readiness and high approval confidence.SVRA
Jefferies Global Healthcare Conference 2026 - MOLBREEVI nears approval for aPAP, backed by strong data and robust launch preparations.SVRA
H.C. Wainwright 4th Annual BioConnect Investor Conference - MOLBREEVI demonstrated strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market.SVRA
Corporate presentation - Q1 2026 net loss rose to $37.3M as regulatory filings advanced and cash reserves remained strong.SVRA
Q1 2026